Context Therapeutics Inc Cash Flow Conversion Efficiency
Context Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Context Therapeutics Inc (CNTX) has a cash flow conversion efficiency ratio of -0.184x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.02 Million) by net assets ($38.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Context Therapeutics Inc (2016–2025)
Cash flow conversion efficiency of Context Therapeutics Inc from 2016 to 2025. This chart illustrates how Context Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Context Therapeutics Inc for real-time trading data and today's change.
Context Therapeutics Inc Cash Flow Conversion Ratio Explained
Context Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Context Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Context Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Context Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BMG Resources Ltd
AU:BMG
|
-0.022x |
|
Huachen AI Parking Management Technology Holding Co Ltd
NASDAQ:HCAI
|
-1.045x |
|
TEKMAR GROUP PLC LS-01
F:6UA
|
N/A |
|
Kwang Jin Ind. Co. Ltd
KQ:026910
|
0.025x |
|
Libet S.A.
WAR:LBT
|
-0.036x |
|
Shin Poong Pap
KO:002870
|
0.008x |
|
Alphawave IP Group PLC
LSE:AWE
|
-0.107x |
|
Hanil Chemical Ind. Co. Ltd
KQ:007770
|
-0.034x |
Annual Cash Flow Conversion Efficiency for Context Therapeutics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Context Therapeutics Inc from 2016 to 2025. Review financial flexibility index of Context Therapeutics Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $60.47 Million | $-26.39 Million | -0.436x | -185.56% |
| 2024-12-31 | $95.27 Million | $-14.56 Million | -0.153x | +91.38% |
| 2023-12-31 | $11.87 Million | $-21.05 Million | -1.773x | -354.84% |
| 2022-12-31 | $34.76 Million | $-13.55 Million | -0.390x | -113.84% |
| 2021-12-31 | $48.27 Million | $-8.80 Million | -0.182x | -398.13% |
| 2020-12-31 | $-16.92 Million | $-1.03 Million | 0.061x | -48.34% |
| 2019-12-31 | $-23.96 Million | $-2.84 Million | 0.118x | +131.22% |
| 2017-12-31 | $58.95 Million | $-22.35 Million | -0.379x | +83.73% |
| 2016-12-31 | $13.12 Million | $-30.57 Million | -2.331x | -- |
About Context Therapeutics Inc
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the de… Read more